If you started a GLP-1 medication such as Ozempic, Wegovy, Mounjaro, or Zepbound and noticed more hair in your brush a few months later, you are not imagining it. Recent studies have linked these medications to a higher rate of hair shedding, and the pattern fits a well-understood process in the hair growth cycle.
Is hair loss a side effect of GLP-1 medications?
A study published in The BMJ in July 2026 compared adults with type 2 diabetes who started a GLP-1 medication with people who started two other classes of diabetes drugs. GLP-1 users had a 37% higher risk of hair loss than people on SGLT-2 drugs and a 68% higher risk than people on DPP-4 drugs. The increase was specific to non-scarring hair loss, the type where the follicles stay intact.
A 2026 review of 24 studies found that semaglutide and tirzepatide showed the most consistent link to hair loss among GLP-1 medications. Higher semaglutide doses used for weight loss were linked to hair loss more often than the lower doses used for diabetes, and women appeared to be affected more than men.
Why shedding happens after rapid weight loss
Each hair on your head follows its own cycle. A follicle grows hair for several years, then rests for a few months before that hair falls out and a new one replaces it. Normally only about 10% of scalp hair is in the resting phase at any time.
Rapid weight loss is a shock to the body, and it can push many follicles into the resting phase at once. Dermatologists call this telogen effluvium. The extra shedding usually appears 2 to 4 months after the trigger, which is why many women don't connect it to the medication they started earlier.
Does the type of medication matter?
Early research suggests it may. A 2026 analysis of patients matched by how much weight they lost found new hair loss was more common with tirzepatide (Mounjaro, Zepbound) than with semaglutide (Ozempic, Wegovy). Among nearly 9,000 women in that analysis, new hair loss within a year was recorded in 5.4% of tirzepatide users and 3.6% of semaglutide users. The study has not yet been peer-reviewed.
What women usually notice
GLP-1 related shedding tends to be spread across the whole scalp. Women describe more hair in the shower drain and on the pillow, a ponytail that feels thinner, or a part that looks wider. Because the follicles stay intact, this is the right time to support the scalp and protect the hair you have.
How to support your hair while you lose weight
Handle hair gently. Hair that is already shedding breaks more easily. A leave-in detangler lets a brush glide through knots instead of pulling, and lower heat settings reduce stress on fragile strands.
Use a daily scalp serum with studied actives. Actsyl-3 Serum contains Redensyl (3%) and Capixyl (2%), two cosmetic actives tested in placebo-controlled clinical studies. In the supplier's 84-day study, 85% of volunteers using a 3% Redensyl lotion showed visible improvement, with 17% fewer hairs in the resting phase. In a separate four-month study, a Capixyl lotion improved the ratio of growing to resting hairs by 46%, while the placebo group declined. Actsyl-3 is non-hormonal and absorbs in seconds, so it fits easily into the routine you already have. Read more about the research.
Keep your prescriber in the loop. If shedding is heavy or comes with patches, mention it at your next appointment so they can look at your overall plan.
The bottom line
Shedding is one of the most common surprises for women on GLP-1 medications, and research now backs up what many have noticed in the mirror. Most customers notice less shedding within 2 to 4 weeks of starting Actsyl, and fuller-looking hair follows with consistent daily use.
References
- Tang H, et al. Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation. BMJ. 2026;394:e100077.
- GLP-1 receptor agonists and hair loss: a systematic review. Science Progress. 2026.
- Marwaha A, et al. New-onset alopecia is significantly higher with tirzepatide than with semaglutide, even after weight-loss matching. Preprints.org, 2026 (not yet peer-reviewed).
- Chang FC, Oakley A. Telogen effluvium. DermNet.
- British Association of Dermatologists. Telogen effluvium.
- Induchem (Givaudan). Redensyl clinical data. Supplier document.
- Lucas Meyer Cosmetics. Capixyl clinical data. Supplier document.
